Consequently, ABCP therapy is the only validated combination regimen of ICIs and platinum-doublet chemotherapy following EGFR-TKI administration, as supported by findings from phase 3 clinical trials involving non-squamous NSCLC patients with EGFR mutations in Japan. This evidence concerns the gene EGFR and non-small cell lung carcinoma.